Get the Stockscreener App
2.48
9.16%
-0.25
Reshape Lifesciences Inc stock is traded at $2.48, with a volume of 532.15K.
It is down -9.16% in the last 24 hours and up +0.81% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
See More
Previous Close:
$2.73
Open:
$2.59
24h Volume:
532.15K
Relative Volume:
0.22
Market Cap:
$3.30M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.064
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-22.01%
1M Performance:
+0.81%
6M Performance:
-97.77%
1Y Performance:
-99.19%
1-Day Range:
$2.45
$2.73
1-Week Range:
$2.45
$3.49
52-Week Range:
$2.23
$312.04
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
2.48 | 6.51M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
ReShape Lifesciences Holds Special Stockholder Meeting - TipRanks
What drives ReShape Lifesciences Inc. stock priceTremendous growth potential - PrintWeekIndia
What analysts say about ReShape Lifesciences Inc. stockPhenomenal capital appreciation - Autocar Professional
Will ReShape Lifesciences Inc. stock split in the near futureOverwhelming profit margins - jammulinksnews.com
ReShape Lifesciences Announces Partial Adjournment of Stockholder Meeting for Asset Sale and Charter Amendment Proposals - Nasdaq
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders - GlobeNewswire
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
Is RSLS a good stock - AInvest
Is ReShape Lifesciences Inc. a good long term investmentHigh-profit stock alerts - jammulinksnews.com
ReShape Lifesciences Inc. Stock Analysis and ForecastTriple-digit profit margins - Autocar Professional
ReShape's New Lap-Band 2.0 FLEX Targets GLP-1 Era: Top Surgeons Gather for Groundbreaking Summit - Stock Titan
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit - GlobeNewswire
ReShape Lifesciences Hosts Special Meeting of Stockholders on July 24, 2025 - AInvest
ReShape Lifesciences Board Unanimously Recommends Merger with Vyome Therapeutics and Sale of Assets to Biorad Medisys - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - Yahoo.co
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 - GlobeNewswire
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 - Benzinga
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
How high can ReShape Lifesciences Inc. stock price go in 2025Free Access to Community - Newser
ReShape Lifesciences Announces Merger with Vyome Therapeutics - The Globe and Mail
Why ReShape Lifesciences Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes ReShape Lifesciences Inc. stock price move sharplyFree Join Group - Newser
How ReShape Lifesciences Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
ReShape Lifesciences Loans $200K to Vyome Therapeutics - TipRanks
ReShape Lifesciences to receive patent for swallowable balloon device - Investing.com
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Game-Changing Patent: ReShape's New Self-Degrading Weight Loss Balloon Could Transform Obesity Treatment - Stock Titan
RSLS 425及美國證券交易委員會申報文件 - Yahoo 財經
ReShape Lifesciences: Navigating Regulatory Recovery – Is This Turnaround Sustainable? - AInvest
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):